NCT00066573 · OUTCOME

Clinical Fracture Rate: Number of Participants With Bone Fractures.

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer · Source last updated 2023-08-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures.

Patients receive oral exemestane (25 mg) once daily for 5 years. exemestane: Given orally

Patients receive oral anastrozole (1 mg) once daily for 5 years. anastrozole: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Exemestane	3789
Anastrozole	3787

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Exemestane	358	Not reported	Not reported	Not reported	Not reported
Anastrozole	354	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures.

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

8 years

title

Clinical Fracture Rate: Number of Participants With Bone Fractures.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice